Bispecific antibody · Immune activation, directed at CD3 (CD3E) and CD19 · developed by ASTRAZENECA
Surovatamig is a fully human bispecific IgG4 T-cell engager antibody that binds CD3 on cytotoxic T lymphocytes and CD19 on B cells. By bridging the two, it redirects T cells to CD19-expressing cells, and it is being studied in large B-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
Large B-cell Lymphoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →